Effect of hormone therapy on the enteroinsular axis

Menopause

Volumn 12, Issue 5, 2005, Pages 630-638

  Sztefko, Krystyna ^a   Rogatko, Iwona ^a   Milewicz, Tomasz ^b   Krzysiek, Józef ^b   Tomasik, Przemyslaw J ^a   Szafran, Zdzislaw ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

CCK; GIP; GLP 1; Glucose tolerance; Insulin

Indexed keywords

CHOLECYSTOKININ; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENDOCRINE FUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONAL THERAPY; HUMAN; INSULA; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; INSULIN RESPONSE; MENOPAUSE; POSTMENOPAUSE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BLOOD GLUCOSE; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FASTING; FEMALE; GASTROINTESTINAL HORMONES; HUMANS; INSULIN; MIDDLE AGED; POSTMENOPAUSE; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES;

EID: 25444475763     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000172266.47820.43     Document Type: Article

References (38)

1. Zhang Y, Howard B, Cowan L, et al. The effect of estrogen use on levels of glucose and insulin and risk of type 2 diabetes in postmenopausal women. Diabetes 2002;25:500-504.
2. The North American Menopause Society (NAMS). Effect of menopause and estrogen replacement therapy on women with diabetes mellitus. Menopause 2000;7:87-95, 98-104.
3. Frayn N. Visceral fat and insulin resistance-causative or correlative? Br J Nutr 2000;83:71-77.
4. Wu SI, Chou T, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol 2001;54:117-120.
5. Grodstein F, Hennekens CH, Colditz G, et al. Age at natural menopause and risk of cardiovascular disease. Arch Int Med 2002;10:1061-1066.
6. Gesthovel F, Sullivan R. Relationship between obesity and insulin and lipoprotein metabolism in postmenopausal women. Arch Gynecol Obstet 2002;261:35-37.
7. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead M, Stevenson JC. Effects of oral and transdermal 17β estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000;49:742-747.
8. Kimmerle R, Heinemann L, Heise T, et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999;6:36-42.
9. McIntyre N, Holdsworth CC, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-21.
10. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent releasing polypeptide. Endocrinol Rev 1995;16:390-410.
11. Meneilly GS, Ryan AS, Minaker KL, Elahi D. The effect of age and glycemia level on the response of the β-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin. J Clin Endocrinol Metab 1998;83:2925-2932.
12. McConnell JG, Alam MJ, O'Hare MM, Buchanen KD, Stout RW. The effect of age and sex on the response of enteropancreatic polypeptide to oral glucose. Age Aging 1993;12:54-62.
13. Rehfeld JF. Effect of gastrin and its C-terminal tetrapeptide amide on insulin secretion in man. Acta Endocrinol 1971;66:169-176.
14. Nugent AG, Leung KC, Sullivan D, Reutens A, Ho KK. Modulation by progestagens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol (Oxf) 2003;59:690-698.
15. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators: Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-1595.
16. Salomaa V, Rasi V, Pekkanen J, et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK Hemostasis Study. Arterioscler Thromb Vasc Biol 1995;15:1549-1555.
17. Zhang Y, Howard BV, Yeh J, et al. The effect of estrogen use on level of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women. Diabetes Care 2002;25:500-504.
18. Cagnacci A, Soldani R, Carriero P, Oletti AM, Fioretti P, Melis GB. Effect of low dose of transdermal 17-beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396-1400.
19. Godsland IF, Stevenson JC. Postmenopausal hormone replacement therapy in insulin metabolism: effects of route of administration and implications for disease and diabetic risk. Br J Clin 1996;86:1-5.
20. Godsland IF, Gangar K, Walton K, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
21. Colacurci N, Zarcone R, Mollo A, Passaro M, De Seta L, De Francisas P. Effects of hormone replacement therapy on glucose metabolism. Panminerva Med 1998;40:18-21.
22. Godsland IF, Manassiev NA, Felton CV, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004;60:541-549.
23. Soranna L, Cucinelli F, Pern C, et al. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women. J Endocrinol Invest 2002;25:547-550.
24. Gaspard UJ, Wery OJ, Scheen AJ, et al. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 1999;2:93-100.
25. Cucinelli F, Paparella P, Soranna L, et al. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 1999;140:215-223.
26. Cowan LD, Go OT, Howard BV, et al. Postmenopausal estrogen use, and cardiovascular disease risk factors in American Indian women. The Strong Heart Study. J Women's Health 1997;6:441-449.
27. Oben J, Morgan L, Fletcher J, Marks V. Effect of the enteropancreatic hormones: gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide on fatty acid synthesis in expiants of rat adipose tissue. J Endocrinol 1991;130:267-272.
28. Eckel RH, Fujimoto WJ, Brunzell JD. Gastric inhibitory polypeptide enhances lipoprotein lipase activity in cultured pre-adipocytes. Diabetes 1979;28:1141-1142.
29. Orskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467-1475.
30. Eissele R, Göke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas rat, pig and man. Eur J Clin Invest 2002;22:283-291.
31. Mortensen K, Petersen LL, Orskov C. Colocalization of GLP-1 and GIP in human and porcine intestine. Ann NY Acad Sci 2000;921:469-472.
32. Nauck MA, Hornberger E, Siege EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-498.
33. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones: glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31:665-670.
34. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1(7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 1993;138:159-166.
35. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K-cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol 1986;112:224-229.
36. Miyawaki K, Yamada Y, Ban NY, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Mat Med 2002;8:738-742.
37. Baum F, Nauck MA, Ebert R, et al. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Digestion 2001;53:189-199.
38. Ahren B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 2000;85:1043-1048.